Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
Puri R, Nissen SE, Arsenault BJ, St John J, Riesmeyer JS, Ruotolo G, McErlean E, Menon V, Cho L, Wolski K, Lincoff AM, Nicholls SJ. Puri R, et al. Among authors: cho l. JAMA Cardiol. 2020 Oct 1;5(10):1136-1143. doi: 10.1001/jamacardio.2020.2413. JAMA Cardiol. 2020. PMID: 32639518 Free PMC article. Clinical Trial.
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Cho L, et al. J Am Coll Cardiol. 2000 Aug;36(2):381-6. doi: 10.1016/s0735-1097(00)00746-4. J Am Coll Cardiol. 2000. PMID: 10933346 Free article.
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
Cho L, Chew DP, Moliterno DJ, Roffi M, Ellis SG, Franco I, Bajzer C, Bhatt DL, Dorosti K, Simpfendorder C, Tuzcu M, Yadav JS, Brener S, Raymond R, Whitlow P, Topol EJ, Lincoff AM. Cho L, et al. Am J Cardiol. 2003 Mar 15;91(6):742-3. doi: 10.1016/s0002-9149(02)03420-3. Am J Cardiol. 2003. PMID: 12633814 Clinical Trial. No abstract available.
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Chacko M, et al. Among authors: cho l. Am Heart J. 2006 May;151(5):1032.e1-7. doi: 10.1016/j.ahj.2006.02.012. Am Heart J. 2006. PMID: 16644331
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience.
Aksoy O, Tuzcu EM, Ellis SG, Whitlow PL, Cam A, Batizy L, Agarwal S, Franco I, Bajzer C, Simpfendorfer C, Raymond R, Nair R, Cho L, Shishehbor MH, Lincoff AM, Kapadia SR. Aksoy O, et al. Among authors: cho l. Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E1-8. doi: 10.1002/ccd.24442. Epub 2012 Nov 8. Catheter Cardiovasc Interv. 2013. PMID: 22508442
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting.
Aggarwal B, Ellis SG, Lincoff AM, Kapadia SR, Cacchione J, Raymond RE, Cho L, Bajzer C, Nair R, Franco I, Simpfendorfer C, Tuzcu EM, Whitlow PL, Shishehbor MH. Aggarwal B, et al. Among authors: cho l. J Am Coll Cardiol. 2013 Jul 30;62(5):409-15. doi: 10.1016/j.jacc.2013.03.071. Epub 2013 May 9. J Am Coll Cardiol. 2013. PMID: 23665371 Free article.
505 results